Matrisys.gif
MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors
11 mars 2019 03h11 HE | MatriSys Bioscience
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
Matrisys.gif
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
03 janv. 2019 03h01 HE | MatriSys Bioscience
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...
Matrisys.gif
MatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directors
12 nov. 2018 04h11 HE | MatriSys Bioscience
SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the...
matrisys_logo_rgb.png
MatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic Dermatitis
21 août 2017 06h00 HE | MatriSys Bioscience
SAN DIEGO, Aug. 21, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, today announced that the first patient...
MatriSys Bioscience announces today publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis
22 févr. 2017 17h39 HE | MatriSys Bioscience
SAN DIEGO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- MatriSys Bioscience (MatriSys Bio) is pleased to announce the publication of breakthrough scientific results from the laboratory of Dr. Richard Gallo at...